REGN
Regeneron Pharmaceuticals, Inc.746.36
-6.26-0.83%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
79.10BP/E (TTM)
17.89Basic EPS (TTM)
41.72Dividend Yield
0%Recent Filings
10-Q
Q3 FY2025 results
Regeneron posted solid Q3 results with total revenues edging up 0.9% y/y to $3.75B, driven by a 27% y/y surge in Sanofi collaboration revenue to $1.62B from stronger Dupixent profits, while U.S. net product sales dipped 18% y/y to $1.59B amid EYLEA's 41% y/y decline to $681M due to biosimilar launches and patient affordability issues—yet EYLEA HD grew 10% y/y to $431M. Operating income fell 13% y/y to $1.03B as R&D expenses climbed 16% y/y to $1.48B on pipeline investments, but net income rose 9% y/y to $1.46B ($13.62 diluted EPS, up 18% y/y) thanks to $756M in other income from investments. Cash flow from operations hit $3.81B YTD, supporting $2.77B in share repurchases and $278K in dividends; quarter-end cash and marketable securities stood at $18.73B, with $2.71B in debt and $750M revolver availability. No material M&A or impairments noted. Biosimilar erosion on EYLEA poses ongoing pricing risks.
8-K
Q3 revenues up 1%, key approvals
Regeneron reported third-quarter 2025 revenues of $3.75 billion, up 1% from last year, fueled by a 28% surge in Sanofi collaboration profits from Dupixent's $4.86 billion global sales, while total EYLEA HD and EYLEA U.S. net sales fell 28% to $1.11 billion amid competition and patient shifts. FDA approvals for Libtayo in high-risk adjuvant CSCC and Evkeeza in young HoFH kids bolster the oncology and rare disease pipelines. Pipeline advances shine. Yet manufacturing snags at Catalent delayed EYLEA HD's pre-filled syringe approval.
8-K
Q3 IPR&D charge disclosed
Regeneron disclosed an $83 million pre-tax acquired IPR&D charge for Q3 2025, stemming from an $80 million upfront payment to Hansoh Pharmaceuticals under a 2025 license agreement. This hit will trim GAAP and non-GAAP net income per diluted share by $0.68. Preliminary results await finalization. Charges like this remain unpredictable.
10-Q
Q2 FY2025 results
Regeneron posted steady revenue growth in Q2 FY2025 ended June 30, 2025, with total revenues up 3.6% y/y to $3.68B, driven by collaboration gains from Sanofi (up 26% y/y to $1.44B, mostly Dupixent profits) and Bayer (up 10% y/y to $415M, EYLEA ex-U.S.), while net product sales dipped 15% y/y to $1.63B as EYLEA U.S. fell 39% y/y to $754M amid biosimilar launches and competition, offset by EYLEA HD U.S. surging 29% y/y to $393M. Operating income held flat at $1.08B y/y, with gross margin on product sales slipping to 83% from 87% due to manufacturing investments; diluted EPS rose 3% y/y to $12.81 on lower shares from repurchases. Cash from operations climbed 17% y/y to $2.19B for H1, yielding free cash flow of $1.74B (derived), bolstering $2.0B cash and $17.5B investments against $2.7B debt; Q2 share buybacks totaled $1.07B. Patent battles over EYLEA biosimilars drag on, risking further erosion.
8-K
Regeneron Q2 revenues rise 4%
Regeneron reported Q2 2025 revenues up 4% to $3.68 billion, fueled by 26% higher Sanofi collaboration from Dupixent's 22% global sales jump to $4.34 billion, while total EYLEA U.S. sales fell 25% to $1.15 billion amid competition and patient shifts. FDA approvals for Lynozyfic in relapsed multiple myeloma and Dupixent in bullous pemphigoid and chronic spontaneous urticaria bolster the oncology and inflammation portfolios. Non-GAAP EPS rose 12% to $12.89. EYLEA HD filings face delays from manufacturing inspections.
ABBV
AbbVie Inc.
223.67-3.78
AMGN
Amgen Inc.
326.74+1.43
BIIB
Biogen Inc.
171.50-4.24
INO
Inovio Pharmaceuticals, Inc.
2.32+0.06
LGND
Ligand Pharmaceuticals Incorpor
192.63-0.25
MRNA
Moderna, Inc.
29.89-0.03
PFE
Pfizer, Inc.
25.53-0.90
RGBP
Regen Biopharma, Inc.
0.01-0.00
RGNX
REGENXBIO Inc.
14.11+0.28
XNCR
Xencor, Inc.
16.55-0.24